Antibe Therapeutics Inc (ATE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Antibe Therapeutics Inc (ATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8017
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; ATB-352 for gout, dental pain, post-surgical pain, and ATB-340 for chronic prevention of cardiovascular disease and cancer chemoprevention. Antibe also offers regenerative medical devices such as CGX-227, CGX-443 and CGX-276 which are indicated for oral and maxillofacial surgery. The company markets its products in Canada and abroad. Antibe is headquartered in Toronto, Ontario, Canada.

Antibe Therapeutics Inc (ATE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Kwang Dong Pharma Enters into Licensing Agreement with Antibe Therapeutics 12
Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 13
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 14
Equity Offering 15
Antibe Therapeutics Raises USD2.38 Million in Private Placement of Common Shares 15
Antibe Therapeutics Raises USD0.7 Million in Second Tranche Public Offering of Units 16
Antibe Therapeutics Raises USD3 Million in Public Offering of Units 18
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 20
Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 21
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 22
Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 24
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$3.5 Million 25
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.2 Million 26
Antibe Therapeutics Completes IPO For US$3 Million 27
Antibe Therapeutics Completes Private Placement Of Common Stock For US$0.2 Million 29
Debt Offering 30
Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 30
Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 31
Antibe Therapeutics Inc – Key Competitors 32
Antibe Therapeutics Inc – Key Employees 33
Antibe Therapeutics Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Jun 29, 2018: Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results 35
Nov 28, 2017: Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update 36
Aug 29, 2017: Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results 37
Mar 01, 2017: Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results 38
Corporate Communications 39
Oct 22, 2018: Antibe Therapeutics establishes business development Advisory Board 39
Product News 40
May 24, 2018: Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology 40
Clinical Trials 41
Apr 26, 2017: Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic 41
Other Significant Developments 42
Apr 03, 2018: Antibe Therapeutics Provides Financial Update 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Antibe Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kwang Dong Pharma Enters into Licensing Agreement with Antibe Therapeutics 12
Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 13
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 14
Antibe Therapeutics Raises USD2.38 Million in Private Placement of Common Shares 15
Antibe Therapeutics Raises USD0.7 Million in Second Tranche Public Offering of Units 16
Antibe Therapeutics Raises USD3 Million in Public Offering of Units 18
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 20
Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 21
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 22
Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 24
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$3.5 Million 25
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.2 Million 26
Antibe Therapeutics Completes IPO For US$3 Million 27
Antibe Therapeutics Completes Private Placement Of Common Stock For US$0.2 Million 29
Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 30
Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 31
Antibe Therapeutics Inc, Key Competitors 32
Antibe Therapeutics Inc, Key Employees 33
Antibe Therapeutics Inc, Subsidiaries 34

List of Figures
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Antibe Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Antibe Therapeutics Inc (ATE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Meiji Holdings Co, Ltd.
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Fuji Electric Co Ltd (6504):企業の財務・戦略的SWOT分析
    Fuji Electric Co Ltd (6504) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • RTI Surgical Inc (RTIX)-医療機器分野:企業M&A・提携分析
    Summary RTI Surgical Inc (RTI), formerly RTI Biologics Inc is a surgical implant company that offers biologic, metal and synthetic implants. The company’s products include spine implants, surgical specialties, sports medicine implants, cardiothoracic and orthobiologics. It offers spine implants such …
  • AbbVie Inc (ABBV):製薬・医療:M&Aディール及び事業提携情報
    Summary AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virolo …
  • Moog Inc (MOG.A):企業の財務・戦略的SWOT分析
    Moog Inc (MOG.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Neos Therapeutics Inc (NEOS):製薬・医療:M&Aディール及び事業提携情報
    Summary Neos Therapeutics Inc (Neos Therapeutics), formerly Neostx Inc, develops, manufactures, and commercializes branded pharmaceuticals. The company’s portfolio includes Adzenys XR-ODT that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients of six years …
  • Aprea AB-製薬・医療分野:企業M&A・提携分析
    Summary Aprea AB (Aprea) discovers and develops novel anticancer compounds targeting the tumor suppressor protein p53. The company’s lead drug candidate includes APR-246, an anti-cancer compound that targets and reactivates the tumor suppressor protein p53, inducing programmed cell death in many hum …
  • Smiths Group Plc (SMIN)-医療機器分野:企業M&A・提携分析
    Summary Smiths Group plc (Smiths Group) is a technology company. It offers products and services for threat and contraband detection, medical devices, energy, and communications industries through five business divisions: John Crane, Smiths Medical, Smiths Detection, Smiths Interconnect and Flex-Tek …
  • Chorus Aviation Inc:企業の戦略・SWOT・財務情報
    Chorus Aviation Inc - Strategy, SWOT and Corporate Finance Report Summary Chorus Aviation Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Imaging Dynamics Company Ltd (IDL):医療機器:M&Aディール及び事業提携情報
    Summary Imaging Dynamics Company Ltd (IDC) is a medical device company that offers medical imaging and digital radiography technology solutions. The company provides detector series, proprietary software and DR series products. Its software products include Magellan medical image processing software …
  • Hargreaves Lansdown PLC:企業の戦略・SWOT・財務情報
    Hargreaves Lansdown PLC - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Lansdown PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • UnitedHealth Group Inc (UNH):企業の財務・戦略的SWOT分析
    UnitedHealth Group Inc (UNH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Dollar General Corporation:企業のM&A・事業提携・投資動向
    Dollar General Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dollar General Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Elos Medtech AB (ELOS B):企業の財務・戦略的SWOT分析
    Elos Medtech AB (ELOS B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aura Energy Ltd (AEE):企業の財務・戦略的SWOT分析
    Summary Aura Energy Ltd (Aura Energy) is a mining and mineral exploration and development company. The company’s business activities include acquisition, exploration, and development of uranium properties in Europe and Africa. Its projects comprise Haggan Uranium Project, Kallsedet Uranium Project, …
  • Insurance and Care NSW:企業の戦略的SWOT分析
    Insurance and Care NSW - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Axonics Modulation Technologies Inc (AXNX):医療機器:M&Aディール及び事業提携情報
    Summary Axonics Modulation Technologies Inc (Axonics) is an independent medical device company that develops and commercializes implantable neuromodulation technology for the treatment of urinary and bowel dysfunction. The company’s Sacral Neuromodulation System (r-SNM) is designed for the treatment …
  • Biofuels Power Corp (BFLS):企業の財務・戦略的SWOT分析
    Summary Biofuels Power Corp (BFLS), is a renewable energy corporation that develops bio fuels. The corporation operates and develops grid-connected biodiesel power electric generation plants. It produces fuels through transesterification of off-spec oils and gasification of waste products such as gl …
  • Toyota Tsusho Corporation (8015)-エネルギー分野:企業M&A・提携分析
    Summary Toyota Tsusho Corporation (Toyota Tsusho) is a diversified general trading and project management company. The company trades steel, aluminum, machinery, electronics, energy, chemicals, and other consumer products. It also provides passenger cars, buses, motorcycles, trucks, used vehicles, e …
  • Societe BIC (BB):企業の財務・戦略的SWOT分析
    Societe BIC (BB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆